Virax Biolabs Group LTD Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 4.99% in Virax Biolabs Group Limited ordinary shares.
NASDAQ
SCHEDULE: Virax Biolabs CEO Boosts Stake to 8.3%
James Foster, CEO of Virax Biolabs Group Limited, has increased his beneficial ownership to 8.3% of the company's ordinary shares.
NASDAQ
SCHEDULE: Virax Biolabs CEO Boosts Stake to 7.3%
James Foster, CEO of Virax Biolabs Group Limited, has reported beneficial ownership of 7.3% of the company's ordinary shares.
NASDAQ
James Foster, CEO of Virax Biolabs Group Limited, reported beneficial ownership of 12.9% of the company's ordinary shares as of December 31, 2023, following a reverse stock split.
NASDAQ
James Foster, CEO of Virax Biolabs Group Limited, has disclosed a beneficial ownership of 24.9% of the company's ordinary shares as of December 31, 2022.